Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) trials

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 6, 2011, Pages 1695-1702

  Buse, John B ^a   Garber, Alan ^b   Rosenstock, Julio ^c   Schmidt, Wolfgang E ^d   Brett, Jason H ^e   Videbæk, Nicoline ^f   Holst, Jens ^g   Nauck, Michael ^h  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^d ST JOSEF HOSPITAL   (Germany)

^e NOVO NORDISK INC   (United States)

^f NOVO NORDISK A S   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h Diabeteszentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; EXENDIN 4; EXENDIN 4 ANTIBODY; HEMOGLOBIN A1C; LIRAGLUTIDE; LIRAGLUTIDE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODY FORMATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; PEPTIDES; RADIOIMMUNOASSAY; VENOMS;

EID: 79956328908     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2822     Document Type: Article

References (32)

1. Jahn EM, Schneider CK 2009 How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations. Nat Biotechnol 25:280-286
2. Berntorp E, Shapiro A, Astermark J, Blanchette VS, Collins PW, Dimichele D, Escuriola C, Hay CR, Hoots WK, Leissinger CA, Negrier C, Oldenburg J, Peerlinck K, Reding MT, Hart C 2006 Inhibitor treatment in haemophilias A and B: summary statement for the 2006 International Consensus Conference. Haemophilia 12(Suppl 6):1-7 (Pubitemid 44741496)
3. van der Voort LF, Gilli F, Bertolotto A, Knol DL, Uitdehaag BM, Polman CH, Killestein J 2010 Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol 67:402-407
4. Vartanian T, Solberg SP, Rice G 2004 Impact of neutralizing antibodies on the clinical efficacy of interferon β in multiple sclerosis. J Neurol 25(1 Suppl 2):II25-II30
5. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS 2007 Immunological responses to exogenous insulin. Endocr Rev 28:625-652 (Pubitemid 47606649)
6. Radermecker RP, Renard E, Scheen AJ 2009 Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab Res Rev 25:491-501
7. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, Wilhelm K, Trautmann M, Shen LZ, Porter LE; DURATION-1 Study Group 2010 DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 33:1255-1261
8. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M 2009 Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 32:1880-1886
9. Amylin Pharmaceuticals Inc. 2009 Byetta prescribing information. Available from: http://pi.lilly.com/us/byetta-pi.pdf (accessed June 24, 2010)
10. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP 1992 Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267:7402-7405
11. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU Study Group 2009 Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 26:268-278
12. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR; LEAD-2 Study Group 2009 Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
13. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B; LEAD-3 (Mono) Study Group 2009 Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373:473-481
14. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, Hale PM, Zdravkovic M, Blonde L; LEAD-4 Study Investigators 2009 Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 32:1224-1230
15. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met + SU Study Group 2009 Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52:2046-2055
16. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L; LEAD-6 Study Group 2009 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
17. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA 2004 Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1-16 (Pubitemid 38900899)
18. U.S. Department of Health and Human Services 2009 Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf (accessed July 19, 2010)
19. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E 2007 Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321:1-18 (Pubitemid 46454303)
20. Rosenstock J, Gumprect J, Szyprowska E, Bednarczyk-Karuzny A, Zychma MJ, During M, Buse J 2009 Pharmacokinetics of liraglutide vs. exenatide in type 2 diabetes: sustained vs. fluctuating concentrations over 24 hours. Diabetes 58(Suppl 1):A150 (abstract 558-P)
21. Schellekens H 2002 Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24:1720-1740; discussion 1719
22. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD 2004 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635 (Pubitemid 39441462)
23. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100 (Pubitemid 40616618)
24. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD 2005 Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091 (Pubitemid 40616617)
25. Schnabel CA, Fineberg SE, Kim DD 2006 Immunogenicity of xenopeptide hormone therapies. Peptides 27:1902-1910 (Pubitemid 43866282)
26. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD 2003 Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377 (Pubitemid 36993328)
27. Heintz G, Waterhouse T, Petrella E, Fischer K, Hiles R 2004 Validation of an ELISA used to determine anti-exenatide antibody cross-reactivity to GLP-1 and glucagon in human plasma samples. AAPS Pharm Sci 6(Suppl 1):1623
28. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang CT, Xu Y, Blonde L, Rosenstock J; Liraglutide Effect Action in Diabetes-6 Study Group 2010 Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 33:1300-1303
29. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, Taylor K 2007 Effects of once-weekly dosing of along-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:1487-1493 (Pubitemid 46871159)
30. Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L; DURATION-1 Study Group 2008 Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet372:1240-1250
31. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE; DURATION-2 Study Group 2010 Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376:431-439
32. Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M 2010 Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 375:2234-2243